- Home
- QH vs CERO Comparison
QH vs CERO Comparison
Compare QH & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QH
- CERO
- Stock Information
- Founded
- QH 2012
- CERO 2017
- Country
- QH China
- CERO United States
- Employees
- QH N/A
- CERO N/A
- Industry
- QH Business Services
- CERO
- Sector
- QH Consumer Discretionary
- CERO
- Exchange
- QH Nasdaq
- CERO Nasdaq
- Market Cap
- QH 6.6M
- CERO 6.1M
- IPO Year
- QH 2020
- CERO N/A
- Fundamental
- Price
- QH $7.11
- CERO $2.02
- Analyst Decision
- QH
- CERO Strong Buy
- Analyst Count
- QH 0
- CERO 2
- Target Price
- QH N/A
- CERO $45.00
- AVG Volume (30 Days)
- QH 671.9K
- CERO 363.3K
- Earning Date
- QH 09-26-2025
- CERO 11-18-2025
- Dividend Yield
- QH N/A
- CERO N/A
- EPS Growth
- QH N/A
- CERO N/A
- EPS
- QH 0.33
- CERO N/A
- Revenue
- QH $357,118,848.00
- CERO N/A
- Revenue This Year
- QH N/A
- CERO N/A
- Revenue Next Year
- QH N/A
- CERO N/A
- P/E Ratio
- QH $19.84
- CERO N/A
- Revenue Growth
- QH N/A
- CERO N/A
- 52 Week Low
- QH $3.93
- CERO $1.93
- 52 Week High
- QH $169.07
- CERO $895.40
- Technical
- Relative Strength Index (RSI)
- QH 56.78
- CERO 20.99
- Support Level
- QH $5.70
- CERO $1.93
- Resistance Level
- QH $7.96
- CERO $5.66
- Average True Range (ATR)
- QH 1.45
- CERO 0.45
- MACD
- QH -0.26
- CERO -0.21
- Stochastic Oscillator
- QH 37.62
- CERO 2.55
About QH Quhuo Limited American Depository Shares
Quhuo Ltd is a gig economy platform focusing on local life services in China. It provide tech-enabled, end-to-end operational solutions to consumer service businesses, including on-demand delivery solutions, mobility service solutions, housekeeping and accommodation solutions, and other services. Its three operating segments, include (i) on-demand delivery solutions, (ii) mobility service solutions, and (iii) housekeeping and accommodation solutions and other services.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.